Based on years of abundant experience in the in vitro diagnostics (IVD) antibodies development, Creative Biolabs provides a variety of high quality IVD antibodies custom development service of miR-328 marker for the diagnosis of myocardial infarction (MI) and glioma.
MicroRNAs (miRNAs), endogenous, small noncoding RNA molecules, play important roles in the posttranscriptional inhibition through binding to 3'-UTRs of target mRNAs, leading to mRNA degradation and/or translational suppression. They are ubiquitously expressed in diverse of organisms and are evolutionary conserved. Former researches have demonstrated a pivotal role of miRNAs in many biological processes, such as proliferation, cell differentiation, cancers, and cardiovascular diseases. Besides, miRNAs are superior candidate biomarkers for a variety of diseases, due to their excellent features. For example, a majority of miRNA species are extremely stable and readily detectable in the peripheral blood, and the levels of circulating miRNAs are typically changed in individuals with various pathological situations. Candidate biomarkers for AMI should show cardiac-specific expression patterns, and some researches have assessed the diagnostic value of cardiac-enriched miRNAs in the setting of AMI.
Figure 1. The biogenesis of miRNAs. miRNAs are originally transcribed by polymerase II (Pol II) as pri-miRNA transcripts. Then pre-miRNAs are exported from nucleus to cytoplasm by exportin 5 (EXPO5). (Jung. H. J. 2015)
miR-328 Marker of Myocardial Infarction
Acute myocardial infarction (AMI) is still a severe and unsolved clinical issue with high morbidity and mortality. An infarct generally leads to insufficient blood supply and oxidative stress, which induce necrosis of cardiac tissue, pathological remodeling, and left ventricular dysfunction. Therefore, early and efficient diagnosis of AMI is indispensable for optimal treatment outcome and may be promoted by the determination of novel predictors. Recently, high-sensitivity assays relied on specific biomarkers allowing earlier AMI diagnosis has become available in clinical practice. Researches have indicated that plasma miR-328 and miR-134 act as potential biomarkers in early diagnosis for AMI. What's more, the miRNA levels were closely connected with the 6-month mortality or development of heart failure after infarction.
Figure 2. miRNAs inﬂuence calcium and nuclear factor of activated T cells (NFAT) signaling in the heart. miR-328 plays an important role in this process. (Kumarswamy, R. 2013)
miR-328 Marker of Glioma
Human glioma is one of the most aggressive and lethal malignant primary brain tumors, which is the main cause of cancer-related mortality in children and young adults. Based on the WHO classification system, human gliomas are able to be divided into four grades: pilocytic astrocytoma (grade I), oligodendroglioma and diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma (grade IV). miR-328 has been proven to be involved in tumorigenesis and tumor development in human gliomas. It has also demonstrated that microRNA-328 may be a useful prognostic marker in human glioma by inhibiting invasive and proliferative phenotypes of malignant cells. Besides, loss of miR-328 expression may stimulate improved tumor progression and adverse outcome by enhancing cellular proliferation and invasion.
With the rapid development of IVD market, IVD antibodies are widely used for the diagnosis of a variety of diseases. Creative Biolabs offers various high-affinity IVD antibody development services for miR-328 marker to meet every customer's requirements.
Creative Biolabs also provides other IVD antibodies. Please feel free to contact us for more information and a detailed quote.
For lab research use only.